UrgoStart Contact

Efficacy:

• Reduction in healing time thanks to its patented TLC-NOSF matrix.⁽⁵⁾

Practicality:

• Maintenance of a moist environment that promotes healing
• Atraumatic and painless removal
• UrgoStart Contact is a highly conformable dressing
• UrgoStart Contact can be used in deep cavity wounds.

The efficacy of TLC-NOSF on the reduction of healing time has been demonstrated in double-blind, randomised controlled clinical studies ^(2,3,4) and by an analysis of observational studies.⁽⁵⁾ The earlier TLC-NOSF treatment is started, the more effective it is.⁽⁵⁾

Finally, UrgoStart Contact is always used as part of a global management approach, along with appropriate etiological treatment.

UrgoStart Contact is used in patients with leg ulcers, diabetic foot ulcers and pressure ulcers, from whenever granulation tissue appears until complete healing.

Contraindications:

• To prevent any risk of delay in appropriate treatment, UrgoStart Contact is contraindicated in cancerous wounds and in fistular wounds demonstrating deep abscess formation.
• Do not use UrgoStart Contact in the event of known sensitivity to the dressing.

1. Wound preparation:

• Clean the wound using the conventional care protocol.
• If an antiseptic has previously been used, rinse the wound carefully with normal saline before applying UrgoStart Contact.
• Carefully dry the skin around the wound.
• UrgoStart Contact can be cut using sterile scissors to fit the dressing size to the wound if necessary.

2. Dressing application:

• Remove the protective tabs.
• Apply the dressing and cover with a secondary dressing adapted to the exudate volume and secure in place using a stretchy bandage (such as Nylex), multi-stretch adhesive tape or a tubular mesh.
• Apply a compression bandage where prescribed.

3. Dressing changes:

UrgoStart Contact should be changed every 2 to 4 days, and may be left in place for up to 7 days, depending on the exudate volume and the clinical condition of the wound.
The recommended treatment duration is at least 8 weeks.

Precautions for use:

• UrgoStart Contact sticks to latex surgical gloves. It is therefore recommended that gloves be moistened with normal saline to facilitate handling of the dressing.
• If the wound shows signs of significant bacterial colonisation, it is recommended that the bacterial component be treated first before starting treatment with UrgoStart Contact.
• In the event of deep, irregular or fistular wounds, leave part of the UrgoStart Contact dressing visible and accessible outside the wound.
• In the event of an atypical ulcer demonstrating induration or excessive localised granulation, treatment with UrgoStart Contact should only be started after having verified the absence of any ulcer deterioration, to prevent any delay in diagnosis.
• Stinging or even painful sensations have been reported, mainly at the start of treatment, with UrgoStart Contact. These are related to the resumption of the healing process and only warrant suspension of treatment in rare cases.
• In the absence of clinical data relative to uncomplicated acute wounds and in the context of Epidermolysis Bullosa, irrespective of duration, the use of UrgoStart Contact is not recommended.
• UrgoStart Contact must not be used during hyperbaric oxygen chamber therapy without an oxygen mask (risk of combustion due to the presence of fat). This contraindication does not apply for hyperbaric oxygen chamber therapy with an oxygen mask if the oxygen concentration inside the chamber is less than 25% and if UrgoStart Contact is not applied on the area over which the mask is placed.
• Sterile individual packaging, for single use: reuse of a single-use dressing can lead to risks of infection.
• Do not re-sterilise the dressing.
• Check that the sterility protector is intact before use. Do not use if the packaging is damaged.

1. Report to the French minister responsible for Social Security and the French Parliament concerning the evolution of French National Health Insurance charges and products for 2014. July 2013.

2. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.

3. Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511.

4. Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379.

5. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153.